2604-39-9Relevant articles and documents
Structure-activity relationships in fungal nucleobases transporters as dissected by the inhibitory effects of novel purine analogues
Gavriil, Efthymios-Spyridon,Dimitrakis, Spyridon,Papadaki, Georgia,Balaska, Sophia,Lambrinidis, George,Lougiakis, Nikolaos,Marakos, Panagiotis,Diallinas, George,Pouli, Nicole,Mikros, Emmanuel
, p. 240 - 251 (2018)
We have previously rationally designed, synthesized and tested a number of 3-deazapurine analogues, which inhibit the ubiquitous fungal nucleobase transporter FcyB, through binding in its major substrate binding site, by specifically interacting with Asn163. Here, in an effort to further understand the molecular details of structure-activity relationships in all three major nucleobase transporters of fungi, we extend this study by designing, based on our previous experience, synthesizing and testing further 3-deazapurine analogues. We thus identify seven new compounds with relatively high affinity (19–106 μΜ) for the FcyB binding site. Importantly, four of these compounds can also efficiently inhibit AzgA, a structurally and evolutionary distinct, but functionally similar, purine transporter. Contrastingly, none of the new compounds tested had any effect on the transport activity of the uric acid-xanthine transporter UapA, albeit this being a structural homologue of AzgA. Besides the apparent importance for understanding how nucleobase transporter specificity is determined at the molecular level, our work might constitute a critical step in the design of novel purine-related antifungals.
Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy
Gavriil, Efthymios-Spyridon,Doukatas, Aris,Karampelas, Theodoros,Myrianthopoulos, Vassilios,Dimitrakis, Spyridon,Mikros, Emmanuel,Marakos, Panagiotis,Tamvakopoulos, Constantin,Pouli, Nicole
, p. 393 - 409 (2019/05/22)
Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.
4-amino-2-chloro-3-nitro pyridine synthesis method
-
Paragraph 0030-0038, (2017/03/17)
The invention discloses a method for synthesizing 4-amino-2-chlorine-3-nitro pyridine. The method comprises the following steps: adopting 65% nitric acid and concentrated sulfuric acid as mixed acid for nitratlon reaction, wherein the yield of the prepared isomer 4-amino-chlorine-3-nitro pyridine and 4-amino-2-chlorine-5-nitro pyridine is 95 to 98%, the purity is 95 to 99.5%, and subsequently purifying through recrystallization, effectively separating the prepared 4-amino-2-chlorine-3-nitro pyridine and 4-amino-2-chlorine-5-nitro pyridine, wherein the yield of the prepared 4-amino-2-chlorine-3-nitro pyridine is 75 to 85%, the purity of the prepared 4-amino-2-chlorine-3-nitro pyridine is 95 to 99%, the yield of the prepared 4-amino-2-chlorine-5-nitro pyridine is 15 to 25%, and the purity of the prepared 4-amino-2-chlorine-5-nitro pyridine is 95 to 99%. The method is applicable to preparation of 4-amino-2-chlorine-3-nitro pyridine and 4-amino-2-chlorine-5-nitro pyridine, and medicines such as an E1 active enzyme inhibitor, an adenosine homocysteine hydrolase inhibitor, a PLK1 recombinant protein inhibitor and benzimidazole can be further prepared.
